AzTrials
AzTrials

Breast Cancer InvasiveNCT05300412

The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer

An observational study of Breast Cancer Invasive, run by University Clinical Centre of Kosova at 1 site in Kosovo.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study has been to explore whether there is any elevation of Interleukin-7 serum level in the early invasive breast cancer (EIBC) patients in comparison with healthy controls. Read more about this study

Who is it for?
Ages 20 to 70 years, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer Invasive
How many people
275 participants
Where
1 siteKosovo
Study dates
5 Jun 2018to 20 Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: In order to determine the Interleukin-7 serum level, blood samples (10 ml venous blood) have been taken from 213 EIBC patients, from which 100 from Kosovo University Hospital and 113 from Croatian University Hospital, prior to surgery and other oncological treatments, such as chemotherapy, radiotherapy, endocrine therapy or target therapy. On the other hand, the blood samples (10 ml venous blood) have been taken also from other 62 healthy participants, which compose the control group, from whom 32 from Kosovo and the other 30 from Croatia. Blood samples categorized in tubes have been identifiable only by the numbers attributed to participants, and have been stored frozen in temperatures of -20˚C, in order to conduct the analysis later. Patients have been selected as consecutive among women, aged between 20 - 70. Also, the control group has been composed by women, aged between 20 - 70.

Who may be able to join

  • Patients with invasive breast cancer, confirmed with biopsy
  • Operable and without distant metastases.

Who cannot join

  • Patients with acute and/or chronic inflammatory diseases, rheumatoid disease and other malignancies occurring simultaneously
  • Patients receiving immune modulatory therapy
  • Patients previously treated by surgery, chemotherapy, radiotherapy, target therapy or endocrine therapy
  • Patients with dementia or any other psychological disorders unable to willingly participate in the study.
  • Breast tumors or any other confirmed malignancies
  • Any acute or chronic inflammatory disease
  • Receiving immune modulatory therapy

Trial locations and contacts

1 site in 1 country.

Kosovo1 site
  • Faton I. Sermaxhaj, MD

    Pristina, 10000

Other trials in Kosovo

About this study

Official title: The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer: a Cross-sectional, Observational, and Analytical Study

The aim of this study has been to explore whether there is any elevation of Interleukin-7 serum level in the early invasive breast cancer (EIBC) patients in comparison with healthy controls. In addition the correlation between the Interleukin-7 serum level and histopathological characteristics of the tumor, has been evaluated.

We have hypothesized that Interleukin-7 serum level is elevated in the patients diagnosed with early invasive BC in comparison with healthy control group, and positively correlates with the tumor size, poor cell differentiation, lymphovascular and perineural invasion, negative hormone receptors' status, axillary lymph node metastasis, and the high Ki-67 proliferation index. In addition, no difference in the Interleukin-7 serum level exists between the patients recruited in Croatia and Kosovo, respectively.

This cross-sectional, observational, and analytical study has included 213 consecutive patients with EIBC (113 from Croatia and 100 from Kosovo) and 62 healthy participants as the control group (30 from Croatia and 32 from Kosovo). Blood samples have been taken from patients confirmed with breast cancer (BC) by biopsy, prior to surgical intervention and other oncological treatments, as well as from healthy participants. Interleukin-7 serum level has been measured, using "Sandwich" ELISA Immunoenzyme test. In addition, after the surgical intervention, the histopathological specimen examinations and the immunohistochemistry have been performed and analyzed. The differences of the distribution of the numerical variables have been analyzed with Mann-Whitney U test and Kruskal-Wallis ANOVA test. Correlations have been tested with Pearson coefficients. P value <0.05 has been accepted as statistically significant.

Read the detailed description

This cross-sectional, observational, and analytical study has been undertaken in the Clinic of Oncology, University Hospital Center Zagreb, Croatia, and the Department of Thoracic Surgery in the University Clinical Center of Kosovo in Prishtina, Kosovo, from June 2018 until December 2019. In order to determine the Interleukin-7 serum level, blood samples (10 ml venous blood) have been taken from 213 EIBC patients, from which 100 from Kosovo University Hospital and 113 from Croatian University Hospital, prior to surgery and other oncological treatments, such as chemotherapy, radiotherapy, endocrine therapy or target therapy. On the other hand, the blood samples (10 ml venous blood) have been taken also from other 62 healthy participants, which compose the control group, from whom 32 from Kosovo and the other 30 from Croatia. Blood samples categorized in tubes have been identifiable only by the numbers attributed to participants, and have been stored frozen in temperatures of -20˚C, in order to conduct the analysis later.

Patients have been selected as consecutive among women, aged between 20 - 70 who are confirmed to BC, by biopsy, operable and without distant metastases. Patients with pathological conditions, such as acute and/or chronic inflammatory diseases, rheumatoid disease and other malignancies occurring simultaneously, patients receiving immune modulatory therapy, patients previously treated by surgery, chemotherapy, radiotherapy, target therapy or endocrine therapy, patients with dementia or any other psychological disorders unable to willingly participate in the study, have been excluded. The control group has been composed by women, aged between 20 - 70, without breast tumors, confirmed by ultrasound or mammography in the last three months or any other confirmed malignancies, without any acute or chronic inflammatory disease as well as no receiving immune modulatory therapy.

In this study, the Interleukin-7 serum level has been measured, using "Sandwich" ELISA Immunoenzyme test, human Interleukin-7 antibody, and Platinum ELISA using research tools from eBioscience Inc., located in San Diego, CA USA. After the surgery (partial or modified radical mastectomy) with or without axillary lymph node dissection or sentinel lymph node biopsy (SLNB), the histopathological specimen examinations have been performed according to routine practice, and the histopathological and immunohistochemistry features have been evaluated. Cancer staging has been conducted according to tumor node metastasis (TNM)-classification, by the American Joint Committee on Cancer Classification (AJCC). The patients have been classified in accordance to their pathological characteristics, including tumor size, histological types, histological grade, LVI and PNI, metastatic lymph nodes, molecular markers such as; ER, PR, amplification of Her-2/neu, Ki-67 proliferation index, molecular surrogate subtypes according to the St Gallen consensus criteria. The data on age and menopausal status have been also obtained from the patients.

Interleukin-7 serum level has been initially determined in all the study participants, including patients and the control group. Then it has been evaluated if there has been any difference of Interleukin-7 serum level between EIBC patients and control group. After that, appropriate analyzes have been done to see if there is any correlation between Interleukin-7 serum level of the patients and histopathological characteristics of the tumor, as well as age and menopausal status. In addition, the potential difference of Interleukin-7 serum level between patients coming from Croatia and Kosovo has been evaluated.

After checking for normality of distribution, numerical variables have been presented as median and interquartile range. The differences of the distribution of the numerical variables have been analyzed with Mann-Whitney U test and Kruskal-Wallis ANOVA test. Associations between numerical variables have been analyzed as Spearman rank correlation coefficient. Analyses have been performed with statistical software SPSS-22.0. The diagnostic accuracy and the optimal cut point value for Interleukin-7 level between two groups have been obtained based on the value of the area under the ROC curve.

Keywords
Breast cancer, interleukins, interleukin-7, biomarker
Medical subject headings
Breast Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Interleukin-7

    The amount of Interleukin-7 in the blood of the patients is determined in units (pg/ml), and is done using "Sandwich" ELISA Immunoenzyme test, human Interleukin-7 antibody, and Platinum ELISA using research tools from eBioscience Inc., located in San Diego, CA USA.

    Measured: 7 days

Secondary outcomes (9)
  1. Tumor size

    The tumor size is determined by units (cm)

    Measured: 2 months

  2. Histological type of tumor

    The tumors are classified in these histological types: Invasive ductal carcinoma, invasive lobular carcinoma and others.

    Measured: 2 months

  3. Histological grade

    Based on histological grade the tumors are classified as: G1, G2, G3.

    Measured: 2 months

  4. Lymphovascular and perineural invasion

    Based on the lymphovascular and perineural invasion, the tumors are divided in positive or negative.

    Measured: 2 months

  5. Metastatic lymph nodes

    First, all the patients are divided in two groups: involved metastatic lymph nodes and without involved lymph nodes. After that, the involved cases are divided as: N1, N2, N3, based on the number of positive lymph nodes.

    Measured: 2 months

  6. Molecular markers: Estrogen, progesterone, Her2/neu, Ki-67 proliferation index.

    ER, PR, Her-2 status and Ki-67 proliferation index were interpreted according to the criteria of the American Society of Clinical Oncology (ASCO) and St. Gallen International Expert Consensus. According to these recommendations, ER and PR are considered positive if ≥1% of tumor cell nuclei exhibit a positive reaction. According to the same criteria, Her-2/neu expression by immunohistochemistry may range from 0 to 3. If the result is 0 to 1, it is considered negative. In contrast, if the result is 3, it is considered positive. Cases with a value of 2 are considered equivocal and are subject to fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH) analysis. The Ki-67 value was determinated as percentage, from (1 - 100)%.

    Measured: 2 months

  7. Molecular surrogate subtypes of Breast cancer

    Based on the St. Gallen Consensus there are five molecular surrogate subtypes of invasive BC according to the expression of formerly mentioned molecular markers, namely, Luminal A-like, Luminal B/Her-2 negative-like, Luminal B/Her-2 positive-like, Her-2 positive type and Triple negative.

    Measured: 2 months

  8. Age

    The patients are divided based on the age

    Measured: 2 months

  9. Menopausal status

    Based on menopausal status patients are divided in premenopausal and postmenopausal.

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2022
  2. Study start5 Jun 2018
  3. Primary completion10 Sep 2019
  4. Study completion20 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
275 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05300412
Sponsor's protocol ID
grid.412416.4
Status last verified
Mar 2022
First submitted
18 Mar 2022
Last updated
29 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Breast Cancer Invasive, run by University Clinical Centre of Kosova at 1 site in Kosovo.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kosovo. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Interleukin-7 (time frame: 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in